Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259717 | 1.00 | MIF (0.52) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL8126152 | 1.00 | MIF (0.52) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL8125280 | 1.00 | MIF (0.52) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL1962036 | 1.00 | MIF (0.52) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL13201409 | 1.00 | MIF (0.52) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL22832244 | 0.85 | MIF (0.42) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL13696288 | 0.85 | MIF (0.42) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL11128185 | 0.83 | MIF (0.50) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL11128186 | 0.83 | MIF (0.50) | MIFCA1CA2KMT2AMEN1 | |
| SCHEMBL1959830 | 0.83 | MEN1 (0.50) | MIFKMT2AMEN1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62198700-A | — | — | None | — | — | JP | disclosed |
| EP-4676917-A1 | MODULATORS OF SORTILIN ACTIVITY | Vesper Bio Aps (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024184468-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-09-12 | — | — | WO | disclosed |
| EP-4428124-A1 | MODULATORS OF SORTILIN ACTIVITY | Vesper Bio Aps (DK) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-6878735-B2 | Multi-substituted imidazolines and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050020586-A1 | NF-kappaB inhibitors and uses thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004066996-A1 | NF-kB INHIBITORS AND USES THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20030232870-A1 | Multi-substituted imidazolines and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2003-12-18 | — | — | US | disclosed |
| US-20030232998-A1 | NF-kB inhibitors and uses threreof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2003-12-18 | — | — | US | disclosed |
| WO-2003101954-A2 | NF-KB INHIBITORS AND USES THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101969-A1 | MULTI-SUBSTITUDED IMIDAZOLINES AND METHOD OF USE THEREOF | MICHIGAN STATE UNIVERSITY (US) | 2003-12-11 | — | — | WO | disclosed |
| US-5331006-A | Cholecystokinin, antisecretory agents | WARNER-LAMBERT COMPANY (US) | 1994-07-19 | — | — | US | disclosed |
| WO-1992004025-A1 | AMINO ACID ANALOGS AS CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| JP-S62198700-A | L-ASPARTYL-2-METHYL-O-(+), BETA-FENCHYLSERINE METHYL ESTER | TAKASAGO CORP | 1987-09-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | MIF 32/4885CA1 2571/4885CA2 2050/4885 |
| US-20030232998-A1 | NF-kB inhibitors and uses threreof | NFKBIA, IKBKB, IKBKG | MIF 277/4885CA1 4167/4885CA2 3137/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | MIF 4575/4885CA1 1704/4885CA2 2825/4885 |
| US-20050020586-A1 | NF-kappaB inhibitors and uses thereof | NFKBIA, IKBKB, IKBKG | MIF 45/4885CA1 3192/4885CA2 3064/4885 |
| US-20030232870-A1 | Multi-substituted imidazolines and method of use thereof | IKBKB, NFKBIA, IKBKG | MIF 51/4885CA1 3588/4885CA2 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.